Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ITOS |
---|---|---|
09:32 ET | 3326 | 14.58 |
09:34 ET | 100 | 14.44 |
09:36 ET | 500 | 14.39 |
09:38 ET | 300 | 14.44 |
09:39 ET | 133 | 14.435 |
09:50 ET | 825 | 14.46 |
09:52 ET | 1900 | 14.56 |
09:54 ET | 200 | 14.54 |
09:57 ET | 100 | 14.56 |
09:59 ET | 900 | 14.55 |
10:03 ET | 435 | 14.625 |
10:06 ET | 1012 | 14.62 |
10:08 ET | 100 | 14.59 |
10:10 ET | 200 | 14.575 |
10:12 ET | 118 | 14.57 |
10:14 ET | 1500 | 14.5 |
10:15 ET | 200 | 14.49 |
10:17 ET | 200 | 14.48 |
10:19 ET | 400 | 14.4 |
10:21 ET | 452 | 14.38 |
10:24 ET | 2406 | 14.45 |
10:26 ET | 100 | 14.44 |
10:32 ET | 253 | 14.47 |
10:33 ET | 1027 | 14.42 |
10:35 ET | 100 | 14.425 |
10:37 ET | 490 | 14.395 |
10:42 ET | 1500 | 14.39 |
10:51 ET | 200 | 14.435 |
10:53 ET | 400 | 14.4 |
11:02 ET | 700 | 14.42 |
11:11 ET | 600 | 14.4 |
11:13 ET | 1501 | 14.41 |
11:15 ET | 1100 | 14.39 |
11:18 ET | 500 | 14.38 |
11:20 ET | 200 | 14.3775 |
11:24 ET | 100 | 14.39 |
11:27 ET | 222 | 14.41 |
11:29 ET | 500 | 14.4 |
11:31 ET | 100 | 14.4 |
11:33 ET | 360 | 14.37 |
11:36 ET | 460 | 14.33 |
11:38 ET | 500 | 14.33 |
11:40 ET | 100 | 14.31 |
11:44 ET | 300 | 14.3425 |
11:51 ET | 400 | 14.425 |
11:54 ET | 200 | 14.435 |
11:56 ET | 155 | 14.435 |
11:58 ET | 100 | 14.46 |
12:00 ET | 555 | 14.49 |
12:02 ET | 100 | 14.49 |
12:03 ET | 100 | 14.4975 |
12:05 ET | 800 | 14.48 |
12:07 ET | 100 | 14.43 |
12:14 ET | 300 | 14.415 |
12:20 ET | 1257 | 14.36 |
12:23 ET | 855 | 14.37 |
12:34 ET | 100 | 14.375 |
12:36 ET | 725 | 14.375 |
12:38 ET | 700 | 14.36 |
12:39 ET | 405 | 14.355 |
12:41 ET | 100 | 14.33 |
12:45 ET | 506 | 14.334 |
12:50 ET | 710 | 14.27 |
12:52 ET | 3515 | 14.3 |
12:54 ET | 5913 | 14.48 |
12:56 ET | 3127 | 14.52 |
12:57 ET | 100 | 14.56 |
12:59 ET | 500 | 14.56 |
01:01 ET | 481 | 14.54 |
01:03 ET | 600 | 14.57 |
01:06 ET | 2490 | 14.56 |
01:08 ET | 1617 | 14.63 |
01:10 ET | 4810 | 14.65 |
01:12 ET | 400 | 14.65 |
01:14 ET | 1316 | 14.68 |
01:15 ET | 900 | 14.66 |
01:17 ET | 242 | 14.65 |
01:19 ET | 702 | 14.65 |
01:21 ET | 318 | 14.65 |
01:24 ET | 1200 | 14.65 |
01:26 ET | 527 | 14.66 |
01:28 ET | 100 | 14.67 |
01:30 ET | 200 | 14.66 |
01:32 ET | 2236 | 14.695 |
01:33 ET | 200 | 14.72 |
01:35 ET | 100 | 14.74 |
01:37 ET | 1125 | 14.7 |
01:39 ET | 100 | 14.7 |
01:42 ET | 100 | 14.67 |
01:48 ET | 166 | 14.68 |
01:50 ET | 1743 | 14.65 |
01:51 ET | 453 | 14.69 |
01:53 ET | 1100 | 14.6475 |
01:57 ET | 200 | 14.63 |
02:00 ET | 805 | 14.68 |
02:04 ET | 3087 | 14.68 |
02:06 ET | 300 | 14.68 |
02:08 ET | 300 | 14.65 |
02:09 ET | 268 | 14.66 |
02:13 ET | 162 | 14.665 |
02:15 ET | 200 | 14.66 |
02:18 ET | 300 | 14.69 |
02:20 ET | 799 | 14.68 |
02:22 ET | 900 | 14.69 |
02:24 ET | 600 | 14.73 |
02:27 ET | 100 | 14.72 |
02:31 ET | 250 | 14.71 |
02:36 ET | 500 | 14.76 |
02:40 ET | 100 | 14.74 |
02:49 ET | 600 | 14.78 |
02:54 ET | 3507 | 14.85 |
02:58 ET | 400 | 14.81 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Iteos Therapeutics Inc | 528.1M | -3.9x | --- |
Applied Therapeutics Inc | 507.3M | -2.3x | --- |
Arbutus Biopharma Corp | 575.6M | -6.9x | --- |
Altimmune Inc | 525.4M | -4.0x | --- |
Taysha Gene Therapies Inc | 461.0M | -1.7x | --- |
Northwest Biotherapeutics Inc | 543.6M | -7.0x | --- |
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $528.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.39 |
EPS | $-3.78 |
Book Value | $16.05 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.